TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12629071
Drug: High-adjusted dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-adjusted dose, 4.44 MBq (120 micro Ci)/g thyroid adjusted for 24 h radioiodine uptake
Study: 12629071
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose methods
Study: 12629071
Drug: Adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted dose methods
Study: 8853810
Drug: Heparin-coated CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated CPB circuit (Duraflo II)
Study: 6228500
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg t.i.d.)
Study: 31983105
Drug: Concomitant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy with IMRT
Study: 31983105
Drug: Concomitant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy with 3DCRT
Study: 10537435
Drug: AHA step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AHA step II diet plus simvastatin (mean dosage 8.11 mg/day)
Study: 7703634
Drug: Replenishing Qi
Normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replenishing Qi and Invigorating Spleen (RQIS) combined with chemotherapy
Study: 3131389
Drug: Adjunctive lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive lithium
Study: 29512900
Drug: Dasatinib at
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib at 50 mg/m² and crizotinib at 215 mg/m² once daily
Study: 29512900
Drug: Dasatinib at
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib at 50 mg/m² and crizotinib at 130 mg/m² or 100 mg/m² twice daily
Study: 26900386
Drug: L-citrulline 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline 2.4 g/day for 7 days, then 2.4 g 1 hour before cycling trial
Study: 26900386
Drug: L-citrulline 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline 2.4 g/day
Study: 24299932
Drug: Prophylactic variable
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic variable rate phenylephrine infusion starting at 0.75 μg/kg/min (group P)
Study: 24299932
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of normal saline (group S)
Study: 20371662
Drug: Vandetanib 100
Normalized name: vandetanib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 100 mg/d
Study: 18759067
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day zinc sulfate for 2 weeks
Study: 18759067
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg estrogen + 5 mg medroxyprogesterone acetate/day for 2 weeks
Study: 18759067
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg estrogen + 5 mg medroxyprogesterone acetate/day and 15 mg/day zinc sulfate for 2 weeks
Study: 27110636
Drug: Non-treatment-seeking comparison
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment-seeking comparison group
Study: 24407920
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg/day) for 6 months
Study: 21842174
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Bemiparin)
Study: 21842174
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (LDA)
Study: 10333390
Drug: Amnioinfusion (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amnioinfusion (normal saline at room temperature infused at 10 mL/min for 60 min, then 3 mL/min until delivery)
Study: 10333390
Drug: Control (antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (antibiotics and acetaminophen without amnioinfusion)
Study: 7695166
Drug: Pravastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin therapy started one month before PTCA
Study: 7654891
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg daily
Study: 2262119
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg for attacks
Study: 6892812
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine injections (2-3 mg in 10 cc saline solution 0.9%)
Study: 28864688
Drug: Propofol plus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol plus 0.5-0.8 μg/kg fentanyl
Study: 28864688
Drug: Propofol plus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol plus 0.05-0.08 μg/kg sufentanil
Study: 28864688
Drug: Propofol plus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol plus 0.04-0.05 mg/kg dezocine
Study: 28864688
Drug: Propofol plus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol plus 0.04-0.05 mg/kg oxycodone
Study: 28864688
Drug: Propofol (2.4-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.4-3 mg/kg) plus 2-2.5 mL saline
Study: 25365866
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Cycloferon 5% liniment and Polyoxidonium with MetrogilDenta gel
Study: 25365866
Drug: MetrogilDenta gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: MetrogilDenta gel
Study: 17233817
Drug: Observation (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (as maintenance therapy)
Study: 14766686
Drug: Remifentanil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (5 microg.kg(‐1).hr(‐1) infusion, 25 microg boli, refractory period of five minutes)
Study: 14766686
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg.kg(‐1).hr(‐1) infusion, 0.5 mg.kg(‐1) boli, refractory period of ten minutes)
Study: 11942868
Drug: Intramuscular ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular ketoprofen
Study: 162675
Drug: Isoxsuprine 10
Normalized name: isoxsuprine 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoxsuprine 10 mg, acetaminophen 250 mg, caffeine 30 mg
Study: 31429790
Drug: Yi-Zhi-An-Shen granules
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yi-Zhi-An-Shen granules (YZASG) administered three times a day for 16 weeks
Study: 31429790
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered three times a day for 16 weeks
Study: 24673165
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of oral zinc sulphate tablets for 14 days
Study: 21048508
Drug: Latanoprost-timolol-fixed combination
Normalized name: latanoprost / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost-timolol-fixed combination (LTFC)
Study: 19636660
Drug: Bupivacaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (5 mg)
Study: 19636660
Drug: Neosaxitoxin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neosaxitoxin (10 microg) plus Bupivacaine (5 mg)
Study: 9216352
Drug: Combined medical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined medical and cognitive-behavioral treatment
Study: 31528769
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide (TA) injection
Study: 29040223
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg·d)
Study: 25445081
Drug: Social Effectiveness
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Effectiveness Therapy (SET)
Study: 17872493
Drug: Mepolizumab 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 250 mg
Study: 17872493
Drug: Mepolizumab 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 750 mg
Study: 555600
Drug: Pirbuterol 15
Normalized name: pirbuterol 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirbuterol 15 mg
Study: 19514
Drug: Metaproterenol 20
Normalized name: metaproterenol 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol 20 mg
Study: 555600
Drug: Pirbuterol 10
Normalized name: pirbuterol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirbuterol 10 mg
Study: 25914334
Drug: Trigonella foenum‐graecum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigonella foenum‐graecum seed extract (libifem) at a dose of 600 mg/day
Study: 24096616
Drug: Amlodipine/losartan 5/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/losartan 5/50 mg or 5/100 mg
Study: 9390667
Drug: Acetazolamide (ACZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACZ) - 3 oral doses (14, 8, and 2 hours prior to testing)
Study: 26387039
Drug: Gefitinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib monotherapy (250 mg/body) for 8 weeks followed by cisplatin and docetaxel (40 mg/m2) on days 1, 8, 29, and 36, and concurrent 3‐dimensional conformal thoracic radiotherapy (2 Gy daily for 5 days a week to a total of 60 Gy)
Study: 26387039
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and docetaxel (40 mg/m2) on days 1, 8, 29, and 36, and concurrent 3‐dimensional conformal thoracic radiotherapy (2 Gy daily for 5 days a week to a total of 60 Gy)
Study: 15317320
Drug: Benzylpenicilloyl-polylysine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzylpenicilloyl-polylysine (5 mg/mL)
Study: 15317320
Drug: PrePen (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrePen (5 mg/mL)
Study: 9013058
Drug: four-pellet group
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: four-pellet group (174 mg NET)
Study: 9013058
Drug: five-pellet group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: five-pellet group (266.5 mg NET)
Study: 7875749
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (preoperative administration)
Study: 7875749
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (postoperative administration)
Study: 3220958
Drug: Hypnotic 'imaginative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnotic 'imaginative involvement'
Study: 3220958
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (Hypnotic, Distraction, Control)
Study: 21938543
Drug: Salsalate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (3 g/day)
Study: 18301136
Drug: Initially conservative
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initially conservative approach (optimal medical therapy with coronary angiography in selected cases with refractory ischemia)
Study: 10731276
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of beta-radiation (28, 35, and 42 Gy)
Study: 1585349
Drug: Intraoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiation therapy combined with hyperthermia
Study: 1585349
Drug: Intraoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiation therapy without hyperthermia (control group)
Study: 2986474
Drug: magnesium trisilicate
Normalized name: Magnesium Trisilicate
DrugBank: Magnesium trisilicate (DB09281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: magnesium trisilicate mixture (BP) 30 ml
Study: 2986474
Drug: metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 10 mg intramuscularly
Study: 2986474
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg orally on the night prior to, and the morning of, surgery
Study: 2986474
Drug: metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 10 mg intramuscularly in combination with oral ranitidine 150 mg
Study: 22868657
Drug: no medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: no medication
Study: 30727947
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (OT) with 8 extra home sessions over 4 supplementary months
Study: 22594985
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (ALA, 630-635 nm wavelength)
Study: 17396436
Drug: Behavior modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior modification intervention (half-hour talk on exercise and diet, repeated after 3 months, weekly diaries, weekly phone calls)
Study: 14557419
Drug: Combined T(4)/T(3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined T(4)/T(3) treatment (liothyronine 10 micro g substituted for 50 micro g of T(4))
Study: 14557419
Drug: Combined T(4)/T(3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined T(4)/T(3) treatment
Study: 14557419
Drug: T(4) treatment
Normalized name: 4-T-BUTYLCYCLOHEXANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: T(4) treatment
Study: 8762789
Drug: One injection
Normalized name: naloxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of penicillin G
Study: 8762789
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V tablets for 6 days
Study: 30336852
Drug: Intraoperative ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative ketamine (0.5 mg kg-1 or 1.0 mg kg-1)
Study: 21337906
Drug: Local conjunctival
Normalized name: Sus scrofa conjunctiva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local conjunctival immunotherapy (LCIT) using mixed Dermatophagoides extracts, administered as eyedrops once daily for 6 months.
Study: 21337906
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution (BSS) as a control for 6 months.
Study: 18683852
Drug: Bacopa monniera
Normalized name: Bacopa monniera leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacopa monniera (2 x 150 mg KeenMind)
Study: 16437190
Drug: Calcium, vitamin
Normalized name: Vitamin B1 with Calcium, Vitamin B1 with Calcium oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium, vitamin D, and sex steroids (without pamidronate)
Study: 12798977
Drug: D-fenfluramine (D-FEN)
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-fenfluramine (D-FEN) (0.5 mg/kg)
Study: 17290328
Drug: Cytokine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine therapy
Study: 8868976
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution as placebo (control group, n = 22)
Study: 21551161
Drug: Bisoprolol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (target dose 10 mg o.d.)
Study: 21551161
Drug: Enalapril (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (target dose 10 mg b.i.d.)
Study: 21551161
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bisoprolol and enalapril
Study: 20684146
Drug: 15% azelaic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% azelaic acid gel applied twice daily for one month
Study: 20684146
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied twice daily for one month
Study: 16359967
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg/d for the first 10 days of the cycle)
Study: 16359967
Drug: Spironolactone plus
Normalized name: Spironolactone Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone plus Diane 35 (spironolactone 100 mg/d; Diane 35 is a combination tablet of 2 mg cyproterone acetate and 35 microg ethinylestradiol/d for 9 months)
Study: 12225339
Drug: Diethylstilboestrol (DES)
Normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylstilboestrol (DES) and aspirin
Study: 9706950
Drug: Fentanyl (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.35 mg)
Study: 3044181
Drug: Nalbuphine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (20 mg)
Study: 15692543
Drug: Ketoprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (100 mg)
Study: 9706950
Drug: 0.9% Sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride (10 mL)
Study: 7832598
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (2 g)
Study: 2226737
Drug: Palliative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative treatment regimens
Study: 27607850
Drug: Nurse-initiated recall
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nurse-initiated recall cards and medication chart checking at handover
Study: 23111657
Drug: Intravenous peramivir
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous peramivir 400 mg once daily
Study: 23111657
Drug: Intravenous peramivir
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous peramivir 200 mg once daily
Study: 23111657
Drug: Oral oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oseltamivir 75 mg twice daily
Study: 23111657
Drug: Intravenous peramivir
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous peramivir 400 mg once daily (in clinically unstable patients)
Study: 23111657
Drug: Intravenous peramivir
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous peramivir 200 mg once daily (in clinically unstable patients)
Study: 23111657
Drug: Oral oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oseltamivir 75 mg twice daily (in clinically unstable patients)
Study: 21501161
Drug: rGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rGH treatment in Group A (n = 8)
Study: 21501161
Drug: rGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rGH treatment in Group B (n = 5)
Study: 21501161
Drug: rGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rGH treatment in Groups A (n = 8) and B (n = 5) combined
Study: 15319705
Drug: Propofol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.2 mg/kg IV bolus)
Study: 9432343
Drug: Amoxicillin 3
Normalized name: amoxicillin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 3 gm/day and lansoprazole (30-180 mg/day) for 2 weeks
Study: 8342972
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C and alternating BCG therapy
Study: 3521480
Drug: Rimantadine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimantadine treatment (200 mg/day for 5 days)
Study: 27185702
Drug: Gel phantom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel phantom training
Study: 19001601
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of elemental calcium with 400 IU of vitamin D(3) daily
Study: 9893199
Drug: Specific IgE
Normalized name: BSA specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific IgE antibodies to lentil extract
Study: 7557504
Drug: Levodopa/Carbidopa administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/Carbidopa administered daily for 3 weeks
Study: 7557504
Drug: Levodopa/Carbidopa (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/Carbidopa (1 week administration)
Study: 26036956
Drug: Water extracts
Normalized name: water birch pollen extract
DrugBank: Betula occidentalis pollen (DB10832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water extracts of Graptopetalum paraguayense (WGP, 4 g day(-1))
Study: 24434439
Drug: Intensive atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive atorvastatin therapy (80 mg/day)
Study: 24434439
Drug: Conventional atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional atorvastatin therapy (20 mg/day)
Study: 26369640
Drug: 0.5 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 Gy single dose
Study: 26369640
Drug: 1.0 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 Gy single dose
Study: 19460871
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of oral lorazepam
Study: 15885165
Drug: Fuhuang Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuhuang Tablets (4 tablets t.i.d. per os)
Study: 15885165
Drug: Zhining Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhining Tablets (4 tablets t.i.d. per os)
Study: 12204869
Drug: Antioxidant vitamin
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamin supplementation (50 mg/day of vitamin E and 250 mg/day of vitamin C)
Study: 6364333
Drug: Tinidazole (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (4 X 500 mg in one single dose)
Study: 6364333
Drug: Tinidazole (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (4 X 500 mg in one single dose) for non-responders